2014
DOI: 10.1134/s0026261714040110
|View full text |Cite
|
Sign up to set email alerts
|

New antibiotics produced by Bacillus subtilis strains

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 11 publications
0
3
0
1
Order By: Relevance
“…For example, Bacillus spp. secrete various antibiotics, such as iturins, fengycins, and mycosubtilins, with different modes of action and different molecular targets (14,17,19,20,49,52). This is consistent with different classes of antimicrobial compounds that have different modes of actions because they interfere with different cellular and physiological processes of the target organisms (47).…”
Section: Discussionmentioning
confidence: 53%
“…For example, Bacillus spp. secrete various antibiotics, such as iturins, fengycins, and mycosubtilins, with different modes of action and different molecular targets (14,17,19,20,49,52). This is consistent with different classes of antimicrobial compounds that have different modes of actions because they interfere with different cellular and physiological processes of the target organisms (47).…”
Section: Discussionmentioning
confidence: 53%
“…However, the new generation of antibiotics should be effective against drugresistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycinresistant E. coli, Pseudomonas aeruginosa, or Acinetobacter baumannii that are very serious causative agents in nosocomial infections and treat public health. Nevertheless, what is essential to control these resistant strains relates to researchers' attempt to exploit such abilities (broad-spectrum, fast killing, and high efficacy) among Bacillus-produced AMPs by using cutting-edge approaches, isolating new strains from unusual environments or making modified types of them using bioengineering [106]. For therapeutic applications in humans, it should not be neglected to study their mechanism of action, immunogenicity, and toxicity before clinical trials.…”
Section: Pharmaceutical Industrymentioning
confidence: 99%
“…Thuricin 7 is the new bacteriocin produced by Bacillus thuringiensis BMG1.7 (Cherif et al 2001). Two unidentified nonproteinaceous amino acids produced by the Bacillus subtilis strain of INA 01085 are also potential as new antibiotics (Malanicheva et al 2014). Bacillus atrophaeus also produces new compounds that are different from bacitracin (Ebrahimipour et al 2014).…”
Section: Csamentioning
confidence: 99%